EA201891141A1 - Новые антиангиогенные слитые полипептиды - Google Patents

Новые антиангиогенные слитые полипептиды

Info

Publication number
EA201891141A1
EA201891141A1 EA201891141A EA201891141A EA201891141A1 EA 201891141 A1 EA201891141 A1 EA 201891141A1 EA 201891141 A EA201891141 A EA 201891141A EA 201891141 A EA201891141 A EA 201891141A EA 201891141 A1 EA201891141 A1 EA 201891141A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fusion polypeptides
fusion
polypeptides
fused
polypeptide
Prior art date
Application number
EA201891141A
Other languages
English (en)
Other versions
EA035586B1 (ru
Inventor
Шейн Ольвилль
Рачида Сихам Бел Айба
Александер Виденман
Original Assignee
Пиерис Острелиа Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пиерис Острелиа Пти Лтд. filed Critical Пиерис Острелиа Пти Лтд.
Publication of EA201891141A1 publication Critical patent/EA201891141A1/ru
Publication of EA035586B1 publication Critical patent/EA035586B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)

Abstract

Изобретение предусматривает слитые полипептиды, содержащие фрагмент, специфичный в отношении Ang-2, и другой фрагмент - в отношении VEGF-A, причем такой слитый полипептид можно применять в качестве антагониста Ang-2 и VEGF-A. Такой слитый полипептид можно использовать во многих фармацевтических применениях, например, в качестве средства, применимого для ингибирования или уменьшения ангиогенеза. Настоящее изобретение также касается способов получения слитых полипептидов, описанных в данном документе, а также композиций, содержащих такие слитые полипептиды. Настоящее изобретение дополнительно относится к молекулам нуклеиновой кислоты, кодирующим такие слитые полипептиды, их аминокислотным последовательностям и способам получения таких слитых полипептидов и молекул нуклеиновой кислоты. Кроме того, в настоящей заявке раскрыты пути применения в терапии и/или диагностике этого слитого полипептида, а также композиций, содержащих один или более таких слитых полипептидов.
EA201891141A 2015-11-30 2016-11-30 Новые антиангиогенные слитые белки EA035586B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15197019 2015-11-30
PCT/AU2016/051168 WO2017091850A1 (en) 2015-11-30 2016-11-30 Novel anti-angiogenic fusion polypeptides

Publications (2)

Publication Number Publication Date
EA201891141A1 true EA201891141A1 (ru) 2018-10-31
EA035586B1 EA035586B1 (ru) 2020-07-10

Family

ID=54754521

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891141A EA035586B1 (ru) 2015-11-30 2016-11-30 Новые антиангиогенные слитые белки

Country Status (12)

Country Link
US (1) US10703810B2 (ru)
EP (1) EP3383921A4 (ru)
JP (1) JP2019505565A (ru)
KR (1) KR20180083943A (ru)
CN (1) CN108699162A (ru)
AU (1) AU2016363668A1 (ru)
BR (1) BR112018010887A2 (ru)
CA (1) CA3004918A1 (ru)
EA (1) EA035586B1 (ru)
MX (1) MX2018006559A (ru)
SG (2) SG10201911499TA (ru)
WO (1) WO2017091850A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
CN109829882B (zh) * 2018-12-18 2020-10-27 广州比格威医疗科技有限公司 一种糖尿病视网膜病变分期预测方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2022199603A1 (en) * 2021-03-25 2022-09-29 Nanjing GenScript Biotech Co., Ltd. Antibody fusion proteins and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
KR100384353B1 (ko) 1994-05-18 2003-10-04 네크타르 테라퓨틱스 인터페론의건조분말제형을제조하기위한방법및조성물
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
ES2251196T3 (es) 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
WO2009156456A1 (en) 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP2411407A1 (en) * 2009-03-27 2012-02-01 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012022742A1 (en) * 2010-08-16 2012-02-23 Pieris Ag Binding proteins for hepcidin
JP6100694B2 (ja) 2010-11-15 2017-03-22 ピエリス ファーマシューティカルズ ゲーエムベーハー グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質
WO2014009465A1 (en) * 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
CA2949405C (en) * 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
MX2017009767A (es) * 2015-01-28 2018-08-15 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
BR112017017530A2 (pt) 2015-02-18 2018-04-17 Sanofi proteínas específicas para pioverdina e pioquelina
AU2016258952C1 (en) 2015-05-04 2020-12-24 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
RU2756318C2 (ru) 2015-05-18 2021-09-29 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3)

Also Published As

Publication number Publication date
JP2019505565A (ja) 2019-02-28
AU2016363668A1 (en) 2018-05-24
CN108699162A (zh) 2018-10-23
MX2018006559A (es) 2019-06-12
CA3004918A1 (en) 2017-06-08
SG11201803732PA (en) 2018-06-28
EA035586B1 (ru) 2020-07-10
KR20180083943A (ko) 2018-07-23
SG10201911499TA (en) 2020-01-30
EP3383921A4 (en) 2019-04-17
EP3383921A1 (en) 2018-10-10
WO2017091850A1 (en) 2017-06-08
US20180334499A1 (en) 2018-11-22
US10703810B2 (en) 2020-07-07
BR112018010887A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
MX2018002831A (es) Polipeptidos.
EA201792047A1 (ru) Новые соединения
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
MX2019003298A (es) Proteinas de union recombinantes y sus usos.
EA201491644A1 (ru) Фармацевтические композиции
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201791841A1 (ru) Новые белки, специфичные к пиовердину и пиохелину
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201501080A1 (ru) Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
EA201691095A1 (ru) Мутантные фрагменты ospa и связанные с ними способы и применение
EA201890434A1 (ru) Антитела к cd154 и способы их применения
PH12016501629A1 (en) Uti fusion proteins
TN2018000180A1 (en) Polypeptides inhibiting cd40l
EA202092769A1 (ru) Антитела против cd63, их конъюгаты и применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM